^
    Back
    Association details:
    Biomarker:FLT3 mutation
    Cancer:Myelodysplastic Syndrome
    Drug:Vanflyta (quizartinib) (FLT3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Excerpt:
    ...- Patients are eligible regardless of their FLT3 mutation status....
    Trial ID:
    NCI-2018-01813
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    3238 Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

    Published date:
    11/02/2023
    Excerpt:
    Therapy with azacitidine in combination with quizartinib for pts with higher-risk MDS and MDS/MPN with FLT3 or CBL mutations has acceptable toxicity profile and is associated with promising responses mainly among FLT3-mutant pts.
    Secondary therapy:
    azacitidine
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2022
    Title:

    INITIAL RESULTS OF PHASE I/II STUDY OF AZACITIDINE IN COMBINATION WITH QUIZARTINIB FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH FLT3 OR CBL MUTATION

    Published date:
    05/12/2022
    Excerpt:
    We designed a phase I/II study of azacitidine in combination with quizartinib for pts with newly diagnosed or previously treated MDS or MDS/MPN with detectable FLT3 and/or CBL mutations….Preliminary data suggest azacitidine in combination with quizartinib for pts with MDS and MDS/MPN with FLT3 or CBL mutations have an acceptable toxicity profile and associated with promising responses.
    Secondary therapy:
    azacitidine
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations

    Published date:
    11/04/2021
    Excerpt:
    We designed a phase I/II clinical trial of Azacitidine in Combination with quizartinib for newly diagnosed patients with MDS...Four patients were enrolled due to FLT3 mutations and 2 due to CBL mutations....All patients have achieved response so far with a total of 5 patients (67%) having achieved marrow CR (mCR) including HI in 1 patient...Preliminary data suggest azacitidine in combination with quizartinib for patients with MDS and MDS/MPN with FLT3 or CBL mutations...
    Secondary therapy:
    azacitidine
    DOI:
    10.1182/blood-2021-153189